22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › NURIX THERAPEUTICS INC. › 2024-2025

NURIX THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and NURIX THERAPEUTICS INC.’s Form 8-K, filed May 19, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 203Asset managers, any item
  • 1,375Fund votes
  • May 19, 2025Meeting date

Results at a glance

Meeting of May 19, 2025: 5 items on NURIX THERAPEUTICS INC.’s Form 8-K, filed May 19, 2025: 3 elected · 2 approved.

Dissent

Significant dissent: 1 director (28.8% against).

Notable dissent: 1 director (17.8% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Rubric Capital (13F, 4.5%, as of September 30, 2026)

Explore NURIX THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by NURIX THERAPEUTICS INC.

These tallies are NURIX THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 19, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

NURIX THERAPEUTICS INC. — official shareholder meeting results, meeting held May 19, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Judith A. Reinsdorf 43,571,416---- 17,651,4643,833,317 71%Elected—
Elect Director: Edward C. Saltzman 50,302,518---- 10,920,3623,833,317 82%Elected—
Elect Director: Roy D. Baynes 60,821,712---- 401,1683,833,317 99.3%Elected—
2. Ratification of Appointment of Independent Registered Public Accounting Firm 64,950,59985,04020,558 ---- 99.9%Approved—
3. Approval, on a Non-binding Advisory Basis, of the Compensation of the Company's Named Executive Officers 49,788,97511,341,36592,540 --3,833,317 81%Approved—

Source: NURIX THERAPEUTICS INC., Form 8-K, filed with the SEC on May 19, 2025 — read the filing on EDGAR.

How asset managers voted at the NURIX THERAPEUTICS INC. 2024-2025 meeting

203 asset managers disclosed a vote on at least one NURIX THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Judith A. Reinsdorf

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

71% Majority: yes · of votes cast

FOR 71%WITHHELD
FOR: 43,571,416WITHHELD: 17,651,464
Details: description as filed, official tally, votes by 64 asset managers

Description as filed by funds: Election of Directors: Judith A. Reinsdorf

NURIX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Judith A. Reinsdorf”): 43,571,416 for, 17,651,464 withheld, per its Form 8-K filed May 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the three nominees for director was elected to serve until the Company's 2028 annual meeting of stockholders and until his or her successor has been elected and qualified, or until his or her earlier resignation or removal.”
Support: 71% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 17,785,352 for, 9,986,181 withheld, 41,376 abstained.

FORWITHHOLD
FOR: 17,785,352ABSTAIN: 41,376WITHHOLD: 9,986,181
Largest asset managers voting on “Election of Directors: Judith A. Reinsdorf” at NURIX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity1,451,2350 09,024,776Mixed
Vanguard4,107,2660 00For
BlackRock3,890,0980 00For
T. Rowe Price3,294,6710 00For
ARK ETF Trust1,538,1870 00For
Charles Schwab551,2280 00For
WASATCH FUNDS TRUST534,5800 00For
Artisan448,6280 00For
Hartford432,3500 00For
PRIMECAP Odyssey Funds212,0000 00For
State Street209,4210 0188For
Dimensional00 0206,716Withhold
Equitable125,5380 063,320Mixed
Victory Capital1,5780 0177,221Withhold
TIAA160,4690 00For
QUANTITATIVE MASTER SERIES LLC118,3860 00For
DRIEHAUS MUTUAL FUNDS00 0114,985Withhold
Northwestern Mutual95,0380 00For
Lincoln Financial51,3000 038,415Mixed
Russell Investments85,0530 00For
John Hancock45,9620 24,4220Mixed
MassMutual70,2390 00For
Tema ETF Trust59,1460 00For
Northern Trust00 052,576Withhold
RBB FUND, INC.00 052,098Withhold

Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).

Elect Director: Edward C. Saltzman

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%WITHHELD
FOR: 50,302,518WITHHELD: 10,920,362
Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: Election of Directors: Edward C. Saltzman

NURIX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Edward C. Saltzman”): 50,302,518 for, 10,920,362 withheld, per its Form 8-K filed May 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the three nominees for director was elected to serve until the Company's 2028 annual meeting of stockholders and until his or her successor has been elected and qualified, or until his or her earlier resignation or removal.”
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 18,438,796 for, 9,321,346 withheld, 10,767 abstained.

FORWITHHOLD
FOR: 18,438,796ABSTAIN: 10,767WITHHOLD: 9,321,346
Largest asset managers voting on “Election of Directors: Edward C. Saltzman” at NURIX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity1,451,2350 09,024,776Mixed
Vanguard4,107,2660 00For
BlackRock3,890,0980 00For
T. Rowe Price3,294,6710 00For
ARK ETF Trust1,538,1870 00For
Charles Schwab551,2280 00For
WASATCH FUNDS TRUST534,5800 00For
Artisan448,6280 00For
Hartford432,3500 00For
PRIMECAP Odyssey Funds212,0000 00For
State Street209,6090 00For
Dimensional00 0206,716Withhold
Equitable125,5380 063,320Mixed
Victory Capital178,7990 00For
TIAA160,4690 00For
QUANTITATIVE MASTER SERIES LLC118,3860 00For
DRIEHAUS MUTUAL FUNDS114,9850 00For
Northwestern Mutual95,0380 00For
Lincoln Financial88,4360 01,279For
Russell Investments85,0530 00For
John Hancock70,3840 00For
MassMutual70,2390 00For
Tema ETF Trust59,1460 00For
Northern Trust52,5760 00For
RBB FUND, INC.52,0980 00For

Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).

Elect Director: Roy D. Baynes

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%
FOR: 60,821,712WITHHELD: 401,168
Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: Election of Directors: Roy D. Baynes

NURIX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Roy D. Baynes”): 60,821,712 for, 401,168 withheld, per its Form 8-K filed May 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the three nominees for director was elected to serve until the Company's 2028 annual meeting of stockholders and until his or her successor has been elected and qualified, or until his or her earlier resignation or removal.”
Support: 99.3% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 27,534,237 for, 225,905 withheld, 10,767 abstained.

FOR
FOR: 27,534,237ABSTAIN: 10,767WITHHOLD: 225,905
Largest asset managers voting on “Election of Directors: Roy D. Baynes” at NURIX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity10,476,0110 00For
Vanguard4,107,2660 00For
BlackRock3,890,0980 00For
T. Rowe Price3,294,6710 00For
ARK ETF Trust1,538,1870 00For
Charles Schwab551,2280 00For
WASATCH FUNDS TRUST534,5800 00For
Artisan448,6280 00For
Hartford432,3500 00For
PRIMECAP Odyssey Funds212,0000 00For
State Street209,6090 00For
Dimensional00 0206,716Withhold
Equitable188,8580 00For
Victory Capital178,7990 00For
TIAA160,4690 00For
QUANTITATIVE MASTER SERIES LLC118,3860 00For
DRIEHAUS MUTUAL FUNDS114,9850 00For
Northwestern Mutual95,0380 00For
Lincoln Financial88,4360 01,279For
Russell Investments85,0530 00For
John Hancock70,3840 00For
MassMutual70,2390 00For
Tema ETF Trust59,1460 00For
Northern Trust52,5760 00For
RBB FUND, INC.52,0980 00For

Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).

Approval, on a Non-binding Advisory Basis, of the Compensation of the Company's Named Executive Officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

81% Approved · of votes cast

FOR 81%AGAINST
FOR: 49,788,975AGAINST: 11,341,365

Prior year: 88.3% for (May 20, 2024 meeting) ▼ 6.8 pts

Details: description as filed, official tally, votes by 202 asset managers

Description as filed by funds: To approve, a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.

NURIX THERAPEUTICS INC.’s own tally for this item (“3. Approval, on a Non-binding Advisory Basis, of the Compensation of the Company's Named Executive Officers”): 49,788,975 for, 11,341,365 against — passed, per its Form 8-K filed May 19, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3. Approval, on a Non-binding Advisory Basis, of the Compensation of the Company's Named Executive Officers”
Support: 81% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 64 asset managers voting on “To approve, a non-binding advisory basis, the compensation of the Company's named executive officers as disclo” at NURIX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity1,451,2359,024,776 00Mixed
Vanguard4,107,2660 00For
BlackRock3,890,0980 00For
T. Rowe Price3,294,6710 00For
ARK ETF Trust1,538,1870 00For
Charles Schwab551,2280 00For
WASATCH FUNDS TRUST534,5800 00For
Artisan448,6280 00For
Hartford432,3500 00For
PRIMECAP Odyssey Funds212,0000 00For
State Street209,56643 00For
Dimensional206,7160 00For
Equitable188,8580 00For
Victory Capital178,7990 00For
TIAA160,4690 00For
QUANTITATIVE MASTER SERIES LLC118,3860 00For
DRIEHAUS MUTUAL FUNDS114,9850 00For
Northwestern Mutual95,0380 00For
Lincoln Financial89,7150 00For
Russell Investments85,0530 00For
John Hancock70,3840 00For
MassMutual70,2390 00For
Tema ETF Trust59,1460 00For
Northern Trust52,5760 00For
RBB FUND, INC.52,0980 00For

Fund voting reports, all 64 managers: 18,731,225 for, 9,033,690 against, 47,994 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 155 asset managers voting on “To approve, a non-binding advisory basis, the compensation of the Company's named executive officers as disclo” at NURIX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity010,016,992 00Against
T. Rowe Price5,013,6520 00For
Commodore Capital LP4,085,5810 00For
Redmile Group, LLC4,051,9270 00For
Deep Track Capital, LP3,452,9100 00For
Wellington2,507,4340 00For
Soleus Capital Management, L.P.2,368,7190 00For
BlackRock1,746,9785,004 00For
PICTET ASSET MANAGEMENT SA1,621,4290 00For
GEODE CAPITAL MANAGEMENT, LLC1,598,0270 00For
State Street1,548,262106 00For
Nikko Asset Management Co., Ltd.756,9760 00For
BESSEMER TRUST Co NATIONAL ASSOCIATION611,8680 00For
Candriam S.C.A.0588,908 00Against
Artisan585,9370 00For
WASATCH ADVISORS LP569,6130 00For
Charles Schwab551,2850 00For
Northern Trust457,3990 00For
DRIEHAUS CAPITAL MANAGEMENT LLC454,4610 00For
Woodline Partners LP404,9680 00For
Point72377,4410 00For
Affinity Asset Advisors, LLC350,0550 00For
Vestal Point Capital, LP321,8990 00For
ArrowMark Colorado Holdings LLC314,7620 00For
Bessemer Trust CO of Delaware, N.A.309,4500 00For

Institutional-manager reports, all 155 managers: 38,661,769 for, 11,034,754 against, 18,947 withheld, 3,824 abstained, 46 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Appointment of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 64,950,599AGAINST: 85,040

Prior year: 100.0% for (May 20, 2024 meeting) ▼ 0.1 pts

Details: description as filed, official tally, votes by 64 asset managers

Description as filed by funds: Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending November 30, 2025.

NURIX THERAPEUTICS INC.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm”): 64,950,599 for, 85,040 against — passed, per its Form 8-K filed May 19, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending November 30, 2025.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 27,806,902 for, 13 against, 5,994 abstained.

FOR
FOR: 27,806,902AGAINST: 13ABSTAIN: 5,994
Largest asset managers voting on “Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public a” at NURIX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity10,476,0110 00For
Vanguard4,107,2660 00For
BlackRock3,890,0980 00For
T. Rowe Price3,294,6710 00For
ARK ETF Trust1,538,1870 00For
Charles Schwab551,2280 00For
WASATCH FUNDS TRUST534,5800 00For
Artisan448,6280 00For
Hartford432,3500 00For
PRIMECAP Odyssey Funds212,0000 00For
State Street209,59613 00For
Dimensional206,7160 00For
Equitable188,8580 00For
Victory Capital178,7990 00For
TIAA160,4690 00For
QUANTITATIVE MASTER SERIES LLC118,3860 00For
DRIEHAUS MUTUAL FUNDS114,9850 00For
Northwestern Mutual95,0380 00For
Lincoln Financial89,7150 00For
Russell Investments85,0530 00For
John Hancock70,3840 00For
MassMutual70,2390 00For
Tema ETF Trust59,1460 00For
Northern Trust52,5760 00For
RBB FUND, INC.52,0980 00For

Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).

Largest NURIX THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 76,234,799 shares outstanding at the time of that meeting.

Fund voting reports: top NURIX THERAPEUTICS INC. shareholders by shares voted on “To approve, a non-binding advisory basis, the compensation of the Company's named executive…”, 2024-2025
#Asset manager % of shares outstanding
1Fidelity 13.74%
2Vanguard 5.39%
3BlackRock 5.10%
4T. Rowe Price 4.32%
5ARK ETF Trust 2.02%
6Charles Schwab 0.72%
7WASATCH FUNDS TRUST 0.70%
8Artisan 0.59%
9Hartford 0.57%
10PRIMECAP Odyssey Funds 0.28%
Institutional-manager reports: top NURIX THERAPEUTICS INC. shareholders by shares voted on “To approve, a non-binding advisory basis, the compensation of the Company's named executive…”, 2024-2025
#Asset manager % of shares outstanding
1Fidelity 13.14%
2T. Rowe Price 6.58%
3Commodore Capital LP 5.36%
4Redmile Group, LLC 5.32%
5Deep Track Capital, LP 4.53%
6Wellington 3.29%
7Soleus Capital Management, L.P. 3.11%
8BlackRock 2.30%
9PICTET ASSET MANAGEMENT SA 2.13%
10GEODE CAPITAL MANAGEMENT, LLC 2.10%

Reported NURIX THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

NURIX THERAPEUTICS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Redmile Group, LLC10,696,314 14.03%Schedule 13G, filed April 24, 2026
FMR (Fidelity)10,332,211 13.55%Form 13F, quarter ended March 31, 2025
FMR LLC10,306,351 13.52%Proxy statement (DEF 14A), proxy filed March 28, 2025
BlackRock7,985,893 10.48%Form 13F, quarter ended March 31, 2025
Baker Bros. Advisors LP6,751,565 8.86%Proxy statement (DEF 14A), proxy filed March 28, 2025
Vestal Point Capital, LP6,500,000 8.53%Schedule 13G, filed May 15, 2026
Deep Track Capital, LP6,345,244 8.32%Schedule 13G, filed May 15, 2026
Vanguard Group4,415,122 5.79%Form 13F, quarter ended March 31, 2025
Commodore Capital LP3,850,000 5.05%Proxy statement (DEF 14A), proxy filed March 28, 2025
Arthur T. Sands, M.D., Ph.D.3,615,207 4.74%Proxy statement (DEF 14A), proxy filed March 28, 2025

Percentages above are of 76,234,799 shares outstanding, as reported by NURIX THERAPEUTICS INC. on its Form 10-Q dated February 28, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At NURIX THERAPEUTICS INC.'s shareholder meeting held May 19, 2025, in the 2024-2025 proxy season, 203 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,375 separate fund positions. On the most widely held item on that ballot — To approve, a non-binding advisory basis, the compensation of the Company's named executive… — NURIX THERAPEUTICS INC.'s filing reports the proposal as approved, with 81% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: NURIX THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 19, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from NURIX THERAPEUTICS INC.’s 10-Q dated February 28, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

NURIX THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “NURIX THERAPEUTICS (NRIX) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/nurix-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.